<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700905</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-934</org_study_id>
    <nct_id>NCT03700905</nct_id>
  </id_info>
  <brief_title>Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy</brief_title>
  <acronym>IMSTAR-HN</acronym>
  <official_title>Multicenter Randomized Controlled Phase III Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Westpfalz-Clinical Center GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter randomized controlled phase III study of nivolumab alone or in combination with&#xD;
      ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant&#xD;
      therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgically treated locally advanced head and neck squamous cell carcinoma often requires&#xD;
      postoperative chemoradiation with high risk of acute and late toxicity. DFS after 2 years is&#xD;
      approximately 70%. Combining anti-PD-1 and anti-CTLA4 as a maintenance therapy may improve&#xD;
      DFS due to anti-tumor effects of immunotherapy by enhancing cross-presentation of tumor&#xD;
      antigens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 21, 2018</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm Ia and Arm Ib are summarized in one Arm, due to central ethics committee, as they both include neoadjuvant and adjuvant treatment compared to Arm II</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>approximately 71 months</time_frame>
    <description>disease free survival (DFS) at 3 years of nivolumab alone or in combination with ipilimumab as adjuvant immunotherapy after adjuvant radio(chemo)therapy in locally advanced resected HNSCC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local regional control (LRC)</measure>
    <time_frame>Time from randomization to date of first observed histologically proven or death, up to 36 month</time_frame>
    <description>Disease assessment (CT/ MRI) and Panendoscopy and FFPE in case of suspicion or recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis free survival (DMFS)</measure>
    <time_frame>Time from randomization to date of first observed histologically proven or death, up to 36 month</time_frame>
    <description>Disease assessment (CT/ MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>until end of study (36 months after end of therapy of the last patient), approximately 71 months</time_frame>
    <description>Follow Up- Visits after end of treatment every 3 months until month 36 after randomization, afterwards every 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity and late morbidity</measure>
    <time_frame>AEs/SAEs should be collected continuously until 12 months after randomization</time_frame>
    <description>Adverse Events Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL): QLQ-C30</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Questionaire EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL): Questionnaire H&amp;N43</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Questionnaire H&amp;N43</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of nivolumab alone group vs control and nivolumab &amp; ipilimumab group vs control in terms of DFS</measure>
    <time_frame>assessed up to 36 month</time_frame>
    <description>We compare disease free survival, defined as time from randomization to date of first observed either histologically proven recurrence (local, locoregional or distant), or death from any cause whatever occurs first, of arm Ia to arm II and of arm Ib to arm II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival depending on PD-L1 Status</measure>
    <time_frame>after surgery, up to 4 weeks after surgery</time_frame>
    <description>Assessment of PD-L1 Status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant/adjuvant Nivolumab and Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery&#xD;
Surgical resection of primary tumor including neck dissection according to standard of care&#xD;
6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only), start within 6 weeks post-surgery&#xD;
Arm Ia:&#xD;
• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months&#xD;
Arm Ib:&#xD;
• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical resection + adjuvant radio(-chemo)therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgical resection of primary tumor including neck dissection according to standard of care&#xD;
6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (40mg/m2) in high risk patients), start within 6 weeks post-surgery&#xD;
Standard follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection of primary tumor</intervention_name>
    <description>Surgical resection of primary tumor including neck dissection according to standard of care</description>
    <arm_group_label>Neoadjuvant/adjuvant Nivolumab and Ipilimumab</arm_group_label>
    <arm_group_label>Surgical resection + adjuvant radio(-chemo)therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Adjuvant radio(-chemo)therapy</intervention_name>
    <description>Risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only)</description>
    <arm_group_label>Neoadjuvant/adjuvant Nivolumab and Ipilimumab</arm_group_label>
    <arm_group_label>Surgical resection + adjuvant radio(-chemo)therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant Nivolumab</intervention_name>
    <description>Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery</description>
    <arm_group_label>Neoadjuvant/adjuvant Nivolumab and Ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant Nivolumab</intervention_name>
    <description>Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months</description>
    <arm_group_label>Neoadjuvant/adjuvant Nivolumab and Ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant Nivolumab and Ipilimumab</intervention_name>
    <description>Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months</description>
    <arm_group_label>Neoadjuvant/adjuvant Nivolumab and Ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven SCC of the oropharynx, oral cavity, hypopharynx, and larynx (not&#xD;
             older than 3 months before randomization)&#xD;
&#xD;
          -  clinical stage III-IVB (T1, N2-3; T2, N2-3; T3, N0-3; T4a, N0-3)&#xD;
&#xD;
          -  Oropharyngeal cancer HPV-negative (p16 immunohistochemistry negative)&#xD;
&#xD;
          -  Primary tumor and neck metastasis must be resectable&#xD;
&#xD;
          -  Written and signed informed consent&#xD;
&#xD;
          -  Performance Status of 0 or 1 using ECOG&#xD;
&#xD;
          -  Male and female with age ≥ 18&#xD;
&#xD;
          -  Curative treatment intent (cM0)&#xD;
&#xD;
          -  Screening laboratory values must meet the following criteria and should be obtained&#xD;
             within 4 weeks prior to randomization&#xD;
&#xD;
               -  WBC ≥ 2000/μL&#xD;
&#xD;
               -  Neutrophils ≥ 1500/μL&#xD;
&#xD;
               -  Platelets ≥ 100 x103/μL&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (if using&#xD;
                  the Cockcroft-Gault formula below):&#xD;
&#xD;
               -  Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in&#xD;
                  mg/dL&#xD;
&#xD;
               -  Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in&#xD;
                  mg/dL&#xD;
&#xD;
               -  AST/ALT ≤ 3 x ULN&#xD;
&#xD;
               -  Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have&#xD;
                  total bilirubin &lt; 3.0 mg/dL)&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP)1 must use appropriate method(s) of&#xD;
             contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30&#xD;
             days plus the time required for nivolumab to undergo five half-lives) after the last&#xD;
             dose of investigational drug&#xD;
&#xD;
          -  WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L&#xD;
             or equivalent units of HCG) within 24 hours prior to the start of nivolumab.&#xD;
&#xD;
          -  Women must not be breastfeeding&#xD;
&#xD;
          -  Men who are sexually active with WOCBP must use any contraceptive method with a&#xD;
             failure rate of less than 1% per year. Men receiving nivolumab and who are sexually&#xD;
             active with WOCBP will be instructed to adhere to contraception for a period of 31&#xD;
             weeks after the last dose of investigational product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients should be excluded if they have an active, known or suspected autoimmune&#xD;
             disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes&#xD;
             mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone&#xD;
             replacement, psoriasis not requiring systemic treatment, or conditions not expected to&#xD;
             recur in the absence of an external trigger&#xD;
&#xD;
          -  Patients should be excluded if they have a condition requiring systemic treatment with&#xD;
             either corticosteroids (&gt; 10 mg daily prednisone equivalents) or other&#xD;
             immunosuppressive medications within 14 days of study drug administration. Inhaled or&#xD;
             topical steroids and adrenal replacement doses &gt; 10 mg daily prednisone equivalents&#xD;
             are permitted in the absence of active autoimmune disease.&#xD;
&#xD;
          -  As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab&#xD;
             combinations, drugs with a predisposition to hepatoxicity should be used with caution&#xD;
             in patients treated with nivolumab-containing regimen.&#xD;
&#xD;
          -  Patients should be excluded if they have had prior treatment with an anti-PD-1,&#xD;
             anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug&#xD;
             specifically targeting T-cell costimulation or immune checkpoint pathways&#xD;
&#xD;
          -  Prior invasive malignancy except controlled skin cancer or carcinoma in situ of cervix&#xD;
&#xD;
          -  Unknown primary (CUP), nasopharyngeal or salivary gland cancer&#xD;
&#xD;
          -  Distant metastatic disease or adenopathy below the clavicles&#xD;
&#xD;
          -  Serious co-morbidity, e.g. high-grade carotid artery stenosis, congestive heart&#xD;
             failure NYHA grade 3 and 4, liver cirrhosis CHILD C. If clinically suspected, further&#xD;
             diagnostic is indicated according to the judgement of the investigator.&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Women of child-bearing potential with unclear contraception&#xD;
&#xD;
          -  Previous treatment for the study cancer with chemotherapy, radiotherapy,&#xD;
             EGFR-targeting agents or surgery exceeding biopsy in head and neck&#xD;
&#xD;
          -  Prior radiotherapy to the region of the study cancer that would result in overlap of&#xD;
             radiation therapy fields&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs or participation in another&#xD;
             clinical trial with any investigational drug within 30 days prior to study screening&#xD;
&#xD;
          -  Patients should be excluded if they are positive test for hepatitis B virus surface&#xD;
             antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating&#xD;
             acute or chronic infection&#xD;
&#xD;
          -  Patients should be excluded if they have known history of testing positive for human&#xD;
             immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)&#xD;
&#xD;
          -  Allergies and Adverse Drug Reaction: History of severe hypersensitivity reaction to&#xD;
             any monoclonal antibody&#xD;
&#xD;
          -  History of allergy to study drug components&#xD;
&#xD;
          -  Social situations that limit compliance with study requirements or patients with an&#xD;
             unstable condition (e.g., psychiatric disorder, a recent history of drug or alcohol&#xD;
             abuse, interfering with study compliance, within 6 months prior to screening) or&#xD;
             otherwise thought to be unreliable or incapable of complying with the requirements of&#xD;
             the protocol&#xD;
&#xD;
          -  Patients institutionalized by official means or court order&#xD;
&#xD;
          -  Deficient dental preservation status or not accomplished wound healing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PD Dr. med. Chia-Jung Busch</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München, Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen</name>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>330604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Erfurt GmbH</name>
      <address>
        <city>Erfurt</city>
        <state>Thüringen</state>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Marienkrankenhaus Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22087</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer. 2009 Mar 1;115(5):922-35. doi: 10.1002/cncr.24123. Review.</citation>
    <PMID>19156911</PMID>
  </results_reference>
  <results_reference>
    <citation>Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011 Dec;47(12):1148-53. doi: 10.1016/j.oraloncology.2011.08.007. Epub 2011 Sep 10.</citation>
    <PMID>21911310</PMID>
  </results_reference>
  <results_reference>
    <citation>Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.</citation>
    <PMID>26028407</PMID>
  </results_reference>
  <results_reference>
    <citation>Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.</citation>
    <PMID>25399552</PMID>
  </results_reference>
  <results_reference>
    <citation>Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.</citation>
    <PMID>25891173</PMID>
  </results_reference>
  <results_reference>
    <citation>Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016 Jul;17(7):956-965. doi: 10.1016/S1470-2045(16)30066-3. Epub 2016 May 27.</citation>
    <PMID>27247226</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 Nov 10;375(19):1856-1867. Epub 2016 Oct 8.</citation>
    <PMID>27718784</PMID>
  </results_reference>
  <results_reference>
    <citation>Hanna GJ, Adkins DR, Zolkind P, Uppaluri R. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. Oral Oncol. 2017 Oct;73:65-69. doi: 10.1016/j.oraloncology.2017.08.008. Epub 2017 Aug 17. Review.</citation>
    <PMID>28939078</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

